(Total Views: 386)
Posted On: 05/25/2019 1:15:58 PM
Post# of 148988
I’m not sure where in the pipeline GILD’s drug(s) we’re at the time the PPS was .24 in 1994, or what their corresponding market cap was, but the comparison may not be similar. The reason I think CYDY could be a 10x bagger sooner is due to the fact that combo will be approved and bringing in revenue in 2020, interim TNBC results will be released later this year (hopefully positive), the Prostate test will starting bringing revenue, and mono therapy is not far away as well.
At a $4 PPS (10x the current PPS), CYDY would have a market cap of approximately $1.2 billion. In my opinion, $1.2 billion is not a difficult market cap to reach if what I mentioned above happens in the next 12 months (minus Mono). Additionally, once CYDY uplifts, institutions will begin to purchase the stock and drive the price higher.
I’d be interested to hear from some of the other more educated and experienced members on a possible valuation of CYDY one year from now with combo revenue, prostate test licensing, and positive TNBC results (assuming they’re positive).
At a $4 PPS (10x the current PPS), CYDY would have a market cap of approximately $1.2 billion. In my opinion, $1.2 billion is not a difficult market cap to reach if what I mentioned above happens in the next 12 months (minus Mono). Additionally, once CYDY uplifts, institutions will begin to purchase the stock and drive the price higher.
I’d be interested to hear from some of the other more educated and experienced members on a possible valuation of CYDY one year from now with combo revenue, prostate test licensing, and positive TNBC results (assuming they’re positive).
(1)
(0)Scroll down for more posts ▼
